ישראל - עברית - Ministry of Health

bayer israel ltd - ibritumomab tiuxetan 1.6 mg/ml - kit for radiopharmaceutical preparation infusion - ibritumomab tiuxetan(90y) - the 90y radiolabelled zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. the benefit of zevalin following rituximab in combination with chemotherapy has not been established.the 90y - radiolabelled zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory cd20+ follicular b-cell non-hodgkin's lymphama ( nhl).

ישראל - עברית - Ministry of Health

isotopia molecular imaging, israel - yttrium (90y) chloride - תמיסה להזרקה - yttrium (90y) chloride 1850 mbq - yttrium (90-y) compounds - ytracis is indicated to be used only for the radiolabelling of carrier molecules which have been specifically developed and authorized for radiolabelling with this radionuclide. radiopharmaceutical precursor - not intended for direct application to patients.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תרכיז להכנת תמיסה לאינפוזיה - daratumumab 20 mg / 1 ml - daratumumab

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab

ישראל - עברית - Ministry of Health

amgen europe b.v. - panitumumab - תרכיז להכנת תמיסה לאינפוזיה - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type kras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type kras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תמיסה להזרקה - daratumumab 120 mg / 1 ml - daratumumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תמיסה להזרקה - rituximab 1400 mg / 11.7 ml - rituximab

ישראל - עברית - Ministry of Health

novartis israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg / 1 ml - rituximab

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab